Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

CDC Issues Fact Sheet On Oral Sex, HIV Transmission
The CDC has released a fact sheet informing people that there is some risk of transmitting HIV to others through oral sex, even though it is much lower than the risk of transmission from vaginal or anal intercourse, the Lakeland Ledger"s "Robin"s Rx: Medical Blogging in Polk County" reports. According to the CDC, many people believe that oral sex is safe or has no risk of transmitting disease. The CDC fact sheet said that abstaining from any sexual activity or engaging in mutual monogamy where both partners are uninfected are the only ways to completely prevent HIV transmission, but that condoms and other barriers between the mouth and genitals can reduce the risk of transmission through oral sex (Adams, "Robin"s Rx: Medical Blogging in Polk County," Lakeland Ledger, 6/4).
generic viagra online
Lab Test: Inject Genes Into The Brain, Fat Disappears
It"s estimated two out of three Americans are now overweight or obese*
News of the day
AARP Analysis Debunks Biologic Drug Industry Myth Association Presses Congress To Bring Less Costly Generics To Market Faster
A new analysis by AARP"s Public Policy
Sexual Health

Accumetrics, Inc. Announces 1000th Patient Enrolled In GRAVITAS Trial

Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company"s VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients. "This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company"s VerifyNow System reduces major cardiovascular adverse events post-PCI. Accumetrics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009